Business context and reporting period
The filing is ZIOPHARM Oncology, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2014—not a filing under the name Alaunos Therapeutics, Inc. ZIOPHARM was a development-stage biopharmaceutical company focused on cancer therapies. Its lead program was the Intrexon-partnered synthetic biology candidate Ad-RTS-IL-12 + veledimex; it had no approved products and generated no product sales.
Financial performance and position
Amounts below are in millions of dollars except per-share figures. The filing does not provide a meaningful product gross margin; reported revenue was collaboration revenue.
- Revenue: Q3 2014 was $0.633 versus $0.200 in Q3 2013; nine-month revenue was $1.033 versus $0.600. The 2014 revenue primarily reflected accelerated recognition of Solasia’s prior $5.0 million upfront payment after the July 2014 agreement amendment.
- Loss: Q3 operating loss was $11.942 versus $9.115; net loss was $6.093 versus $16.713, or $0.06 versus $0.20 per share. For nine months, operating loss was $32.903 versus $50.992; net loss was $21.380 versus $48.203, or $0.21 versus $0.58 per share.
- Expenses: Q3 R&D rose 56% to $9.733, while nine-month R&D fell 39% to $24.621. Q3 G&A declined 7% to $2.842; nine-month G&A declined 19% to $9.315.
- Non-operating item: Fair-value gains on warrant liabilities were $5.847 in Q3 and $11.529 for nine months, compared with a Q3 loss of $7.407 and a nine-month gain of $2.979 in 2013. These noncash gains materially reduced reported net loss.
- Cash flow and liquidity: Nine-month operating cash use was $26.780, investing cash use $0.193, and financing cash inflow $4.891. Cash and equivalents ended at $46.122, down from $68.204 at year-end 2013. Working capital was $36.2 versus $62.5 at year-end.
- Balance sheet: Total assets were $49.109 and total liabilities $12.632. The filing reports no borrowings or interest expense; debt is not identified as a material balance-sheet item. Current liabilities were $11.700. Accumulated deficit was $362.211.
- Equity and commitments: Shares outstanding were 102.684 million at September 30. Contractual obligations totaled $5.818, including $3.462 of operating leases. The company received $3.7 from warrant exercises during the nine months.
Material changes versus the prior comparable period
- Q3 R&D increased as synthetic biology discovery, nonclinical, and clinical activity expanded. Nine-month R&D decreased following the 2013 termination of palifosfamide development in soft-tissue sarcoma, suspended small-cell lung cancer enrollment, and workforce reductions; savings were partly offset by higher synthetic biology spending.
- Nine-month cash used in operations improved by $23.7 versus 2013, principally due to lower R&D spending and restructuring. Cash nevertheless declined $22.1 from year-end 2013.
- Reported net loss improved substantially, but the comparison was affected by changes in warrant fair value, not just operating performance.
- In July 2014, Solasia received an exclusive worldwide license to develop and commercialize darinaparsin; Solasia assumed its development, manufacturing, and commercialization costs. ZIOPHARM recorded $1.0 of revenue in the first nine months and classified the remaining $1.7 of deferred revenue as current.
Outlook, commentary, risks, and unusual items
- Management expected available cash to fund operations into the fourth quarter of 2015, but said additional financing would be needed for longer-term plans. There were no committed additional funding sources; financing could be dilutive or unavailable.
- Management planned to report additional Phase 2 data in melanoma and breast cancer in Q4 2014, pursue multiple IND filings through 2015, and target a Phase 1 brain-cancer study in the first half of 2015, subject to FDA requests for additional nonclinical information. These are forward-looking plans, not assurances.
- The company planned to pause further intratumoral Ad-RTS-IL-12 development in melanoma amid changing standards of care and commercial uncertainty, while prioritizing brain and breast cancer and cell-based programs. It reported severe adverse events in the melanoma study; reported events reversed after veledimex dosing stopped. Breast-cancer enrollment continued.
- Key risks include clinical-trial failure or delay, regulatory and manufacturing uncertainty for novel gene-therapy technology, dependence on Intrexon and other contractors, substantial ongoing losses, and the need for additional capital. The filing also notes that the FDA requested additional nonclinical information before the planned glioma trial.
- Intrexon-related-party exposure is notable: ZIOPHARM expensed $9.1 for Intrexon services in the first nine months of 2014, with $2.3 accrued at quarter-end; a ZIOPHARM director was also Intrexon’s CEO, director, and largest stockholder. The collaboration agreement provides for Intrexon to receive 50% of product net profits or applicable sublicense revenue, subject to its terms.
- Management reported effective disclosure controls and no material change in internal control over financial reporting during the quarter. No material legal proceeding was identified as of September 30, 2014.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing names ZIOPHARM Oncology, Inc., whereas the request metadata names Alaunos Therapeutics, Inc.
- Assess whether the stated cash runway into Q4 2015 remains credible given the $26.8 nine-month operating cash use, planned clinical spending, and absence of committed financing.
- Separate operating performance from warrant-accounting effects when evaluating losses; verify warrant liability valuation assumptions and the timing and terms of warrant expirations and exercises. The filing discusses 8.235 million liability-classified warrants at a $3.93 exercise price and also describes 2009 warrant exercises and expirations; reconcile the applicable tranches and dates.
- Track FDA requirements, trial enrollment, safety findings, and results for Ad-RTS-IL-12 + veledimex, including the planned glioma study and the strategic shift away from intratumoral melanoma development.
- Review the Solasia amendment’s revenue-recognition deliverables and the related licensor payment obligations, as well as the economics, governance, and ongoing costs of the Intrexon relationship.